-

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026.

The schedule for the press release and conference call/webcast is as follows:

  • Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET
  • Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET
  • Domestic Dial-In Number: 877-407-3042
  • International Dial-In Number: 201-389-0864
  • Conference ID Number: 13759527

If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number 13759527.

A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Versions

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio...

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences...

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Back to Newsroom